Insitro

Insitro is a machine learning-driven drug discovery company founded by Stanford professor Daphne Koller. The company generates massive biological datasets using high-throughput experimentation and uses machine learning to extract insights that guide therapeutic development, with initial focus areas in metabolic disease and oncology.

Insitro's approach integrates data generation and machine learning at every stage of drug discovery, from target identification through lead optimization. The company uses human-derived cellular models, including iPSC-derived cells, to generate disease-relevant biological data at scale, then applies ML to identify drug targets and predict which molecules will be effective.

The company has raised over $640 million in funding and established partnerships with Bristol-Myers Squibb and Eli Lilly. Founded on the thesis that better data and better models can fundamentally improve drug discovery success rates, Insitro represents a new paradigm in pharmaceutical research where machine learning is the core methodology rather than an afterthought.